Randomized, Phase II Study Prospectively Evaluating Treatment of Metastatic Esophageal, Gastric, or Gastroesophageal Cancer by Gene Expression of ERCC1: SWOG S1201

Syma Iqbal,Shannon McDonough,Heinz-Josef Lenz,David H. Ilson,Barbara Burtness,Chaitali Singh Nangia,Afsaneh Barzi,Charles J. Schneider,Jane Jijun Liu,Efrat Dotan,Katherine A. Guthrie,Howard S. Hochster

Randomized, Phase II Study Prospectively Evaluating Treatment of Metastatic Esophageal, Gastric, or Gastroesophageal Cancer by Gene Expression of ERCC1: SWOG S1201

2019

Syma Iqbal
Shannon McDonough
Heinz-Josef Lenz
David H. Ilson
Barbara Burtness
Chaitali Singh Nangia
Afsaneh Barzi
Charles J. Schneider
Jane Jijun Liu
Efrat Dotan
Katherine A. Guthrie
Howard S. Hochster

PURPOSEPlatinum-based therapy is the standard of care in patients who have HER2-negative, advanced esophagogastric cancer (AEGC). Retrospective data suggest that intratumoral ERCC1 levels may deter...

Keywords:

Gene expression
Pathology
retrospective data
Gastroesophageal cancer
Phases of clinical research
ERCC1
Cancer
Oncology
Medicine
Internal medicine
standard of care
MEDLINE
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations